Page last updated: 2024-09-04
canertinib and ldc4297
canertinib has been researched along with ldc4297 in 1 studies
Compound Research Comparison
Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (ldc4297) | Trials (ldc4297) | Recent Studies (post-2010) (ldc4297) |
---|---|---|---|---|---|
124 | 9 | 65 | 8 | 0 | 8 |
Protein Interaction Comparison
Protein | Taxonomy | canertinib (IC50) | ldc4297 (IC50) |
---|---|---|---|
Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.053 | |
Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0064 | |
Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0034 | |
Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.711 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Bharate, SB; Raghuvanshi, R | 1 |
Other Studies
1 other study(ies) available for canertinib and ldc4297
Article | Year |
---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |